COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #94 of 260
7/20 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Desbois et al., Research Square, doi:10.21203/rs.3.rs-41653/v1 (Preprint)
Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis
Source   PDF   Share   Tweet
Retrospective 199 sarcoidosis patients showing non-statistically significant HCQ RR 0.83, p=1.0.

Desbois et al., 7/20/2020, retrospective, France, Europe, preprint, mean age 58.8, 13 authors.
risk of COVID-19 case, 16.9% lower, RR 0.83, p = 1.00, treatment 3 of 27 (11.1%), control 23 of 172 (13.4%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit